Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.
Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.
Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 for both oncology and inflammation and a number of epigenetics related lysine methyltransferases, including G9a.
Dr Eddy LittlerChief Executive Officer
Illingworth Research Ltd
Founded as Clinical Development & Support Services Ltd (CDSS) in 1998, Illingworth Research is a Clinical Research Organisation (CRO) providing a wide range of clinical development services to the pharmaceutical, healthcare, biotechnology and medical device industries. We are experts in the management of Phase I to IV clinical trials across many different therapeutic areas. | From our base in Cheshire UK, where we are co-located with our sister company ResearchNurses.co, we offer the ultimate clinical research outsourcing partnership for sponsors across the globe. | We have worked with all types of clients, from start-up biotechnology companies to large international pharmaceutical companies, providing strong sponsor/CRO partnerships to deliver a competitive advantage.
Mr Kieran Casey
PolyTherics is a biotechnology company that applies precision chemistry to develop protein and peptide-based drugs. PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.